DDX53 and colonic neoplasm: To assess the impact on antitumor activity, BALB/c mice with large mouse CLDN18.2+ CT26 colon tumors (mean tumor volume 87 mm3) were submitted to adoptive cell transfer with a subtherapeutic dose of mouse Thy1.1+ CLDN18.2-TCAR T cells followed by two injections (2 weeks apart) of CLDN18.2-LPX or control LPX (Fig. 4A, top row).